- Company
- Sales of Duvie exceeded ₩10 billion in the first half
- by Chon, Seung-Hyun Aug 4, 2020 05:54am
- Chong Kun Dang's developed diabetes drug 'Duvie' exceeded the prescription record of &8361;10 billion in the first half. It is strengthening its market competitiveness with the combination drug 'Duvimet'. According to UBIST on the 31st, the total amount of outpatient prescriptions for Duvie in June increased by 5.9% year-on-year to &8361;1
- Company
- Study of Statins vs Ezetimibe combination therapy is ongoing
- by Eo, Yun-Ho Aug 3, 2020 11:06am
- Studies are being conducted to directly compare Statin monotherapy and Ezetimibe combination therapy to Koreans. Yang-Soo Jang, professor at Yonsei University Severance Hospital, conducted a study comparing the efficacy of high-dose Statins and Ezetimibe combination therapy in primary therapy in patients with dyslipidemia with cardiovascul
- Company
- Next-gen Vemlidy prescription grows solely amid COVID-19
- by Kim, Jin-Gu Aug 3, 2020 11:06am
- The outpatient prescription sales of Gilead Science’s hepatitis B treatment Vemlidy (tenofovir) has gone up by 56 percent compared to the second quarter last year. Although the hepatitis B virus (HBV) infection treatment market size has shrunk amid COVID-19 pandemic, Vemlidy has performed at a satisfying level and salvaged the fall Vire
- Company
- Generics for NOAC will be released
- by Kim, Jin-Gu Aug 2, 2020 09:47pm
- In the oral anticoagulant (NOAC) market, which forms a market of &8361;200 billion annually, the prescription performance of items other than Lixiana has decreased. Generics are gradually increasing sales. The competition in this market is expected to intensify if generics for Xarelto and Pradaxa are released next to generic for Eliquis next
- Company
- Choline alfoscerate companies anxious of returning claims
- by Chon, Seung-Hyun Jul 31, 2020 06:34am
- Companies with cognitive enhancer choline alfoscerate products are to face another hurdle. Specifically, the companies are concerned of the clause stipulating the return of the claimed reimbursement when failing the clinical reevaluation during the pricing renegotiation for a product surging in sales. As South Korea’s Ministry of Food and Drug
- Company
- LG Chem begins development of Zemiglo + SGLT-2 inhibitor
- by Kim, Jin-Gu Jul 31, 2020 06:33am
- LG Chem will develop a combination of DPP-4 inhibitor and SGLT-2 inhibitor. Currently, three items are permitted as a combination, but no drug has been developed by a domestic pharmaceutical company. According to the pharmaceutical industry on the 29th, the MFDS recently approved LG Chem's Phase I trial plan which comparing the pharmacokineti
- Company
- GC Pharma, applied for Phase II clinical trial of GC5131A
- by Kim, Jin-Gu Jul 31, 2020 06:31am
- GC Pharma announced on the 29th that it had applied to the MFDS for a clinical trial phase II plan for COVID-19 blood plasma tx, 'GC5131A'. Samsung Medical Center, Asan Medical Center, Chung-Ang University Hospital, Korea University Ansan Hospital, and Chungnam National University Hospital are targeting 60 people. 'GC5131A' is a Hyperi
- Company
- Big 5 green lit another CDK4/6 inhibitor Verzenio
- by Eo, Yun-Ho Jul 30, 2020 06:18am
- General hospitals in South Korea are entering prescription code for anticancer treatment Verzenio. According to pharmaceutical industry sources on July 28, drug committees at the Big Fives including Seoul National University Hospital, Severance Hospital and Samsung Medical Center, and other major general hospitals like National Cancer Cen
- Company
- 2,000 reimbursed items were registered for 3 months
- by Chon, Seung-Hyun Jul 29, 2020 06:34am
- Pharmaceuticals have launched generic products enormously ahead of the new drug price system. In the last three months, about 2000 generics have been licensed and listed. It is to receive upper limit price before applying cascading drug price system that the later it is registered, the lower the price. The government's restrictions on generics h
- Company
- HCV drug Mavyret prescription goes down by 31% amid COVID-19
- by Kim, Jin-Gu Jul 29, 2020 06:33am
- Although Mavyret (glecaprevir) dominated the hepatitis C treatment market as soon as it was launched, the treatment took a steep fall in prescription volume. The pharmaceutical industry sources argue the 31-percent drop compared to last year would have been impacted by decreased number of patients and COVID-19. According to the pharmace
